Advance in Lecanemab therapy for Alzheimer's disease
QIANG Qi-qi
LIU Pei-jie
CUI Si-meng
QU Qiu-min
Abstract：Deposition of amyloid β-protein(Aβ)in the brain is a key pathogenesis and early change in Alzheimer's disease(AD).Clearing Aβ through anti-Aβ monoclonal antibody drugs is an important strategy for disease-modifying thrapy(DMT).Lecanemab is the first approved anti-Aβ monoclonal antibody durg for early therapy,and growing evidence has shown that Lecanemab could clear Aβ deposition and slow progress of AD.This article systematically summarizes the evidence for Lecanemab in treating AD,the results of the early-phase clinical studies,the phase Ⅲ clinical trials,open label extension(OLE)trials and long-term follow-up data,and ongoing clinical research,with the aim of providing clinical guidance on the safety,efficacy and applicability of AD treatment.
Keywords：Alzheimer diseaseAmyloid beta-peptidesAntibodiesmonoclonalhumanizedDrug therapyReview
Publication Date：2026-02-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：6( 188-193 )